explore -WSS

explore

author：hotspot 2025-09-04 04:25:27 - browse：339

Since the early days of the pandemic, long Covid has haunted us: Even a mild acute infection might leave you with life-altering consequences. And for many, that has, sadly, turned out to be the case. While research suggests long Covid rates are falling, it still affects millions. In June 2023, 6% of Americans reported experiencing long Covid.

But what if long Covid isn’t the right way to think about what they are going through?

On this episode of the First Opinion Podcast, I spoke with Steven Phillips and Michelle A. Williams, authors of a recent First Opinion essay titled, “Long Covid is a new name for an old syndrome.” Steven is a Global Virus Network board member and vice president for science and strategy at the COVID Collaborative; Michelle is the former dean and current Joan and Julius Jacobson professor of epidemiology and public health at the Harvard T.H. Chan School of Public Health.

“Michelle and I have come up with basically a new paradigm that says long Covid is really an old disease, and the more you do deep dives into the history of chronic fatigue syndrome and post-infectious fatigue syndromes, the more you realize that not only are there similarities, but the level of congruence between the two is strikingly high,” Steven said.

The purpose of this new paradigm is to “break the logjam” of the current long Covid discourse and “to try to provide a framework whereby people would think about long Covid in a different way in a way that would be more productive,” Michelle told me.

We discussed the history of post-infectious disease syndrome, what rethinking long Covid might mean for research, and the ways the health care system fails chronically ill patients.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Medicare slashes safety net hospital payments by nearly $1 billion

knowledge

WSS

FDA panel to weigh approval of NurOwn, controversial ALS drug

FDA scientists endorse Pfizer/BioNTech Covid

Thermo Fisher plant for manufacturing gene therapies to expand

Intarcia’s device

FDA panel to weigh approval of NurOwn, controversial ALS drug

It costs an awful lot of money to give away a kidney

focus

explore

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

Senate HELP committee spars over health care workforce policies

In age of alternative facts, a scholarly course on calling out crap

Heart disease in astronauts blamed on cosmic radiation

Activists slam private health insurers over coverage restrictions

Physicians aren't 'burning out.' They're suffering from moral injury

Alkermes shareholders re

Hearing on Medicare drug price negotiation gets unusually heated

State Dept. review finds Biden bears some blame for Afghanistan failures

Biotech lab space demand falls sharply

Wikipedia

How Vertex's cystic fibrosis drug is changing patients' lives

EpiPen alternative approval delay highlights citizen petition issue

FDA approves Sage Therapeutics’ rapid

'Null' research findings aren't empty of meaning. Let's publish them

Florida officials tell state schools to teach AP Psychology 'in its entirety'

CDC's new outbreak response network to include Northeastern

hotspot

knowledge

explore

explore